SPUTA VACUUMER®: A Paradigm Shift in Airway Clearance
Reversing the Concept: “Don’t Chase Sputum. Make it Come to You.”
Traditional suction is painful and risky because it requires inserting a tube deep into the lungs. SPUTA VACUUMER® changes everything. By applying a unique “Vacuuming” theory, we move the sputum to the catheter, not the other way around. This enables safe, simple, and low-invasive suction for any practitioner.
Estimated Business Value
JPY 1.9 Billion+
Target Market
Global “Blue Ocean” in Airway Management
Disclaimer: This valuation is a conceptual estimate by an AI and is not a substitute for an official market transaction appraisal. It should be used for reference purposes only.
The Core Innovation
The Challenge: A Reality of Pain and Risk
Traditional suction procedures inflict severe distress (gagging, pain) and complication risks (airway damage, hypoxemia) on patients. Existing alternatives like mechanical insufflation-exsufflation (MI-E) face significant hurdles: High Cost and Complex Operation.
STONY’s Solution: The “Vacuuming” Paradigm Shift
We developed a universal connector that converts standard suction pressure into a therapeutic “Vacuuming” force.
Universal: Compatible with standard endotracheal tubes and LMAs.
Low Cost: Uses existing suction pumps.
High Safety: No need for deep insertion.
For Patients: Liberation from Pain
Transforms a “torturous procedure” into “gentle care.” Dramatically improves QOL by reducing coughing fits and mucosal damage.
For Caregivers: Skill-Free Safety
Standardizes the technique. Enables even less-experienced staff or family members to perform safe suctioning, reducing the burden of care and risk of human error.
For Business: Recurring Revenue
Establishes a powerful Recurring Revenue Model based on high-volume disposables. A massive, untapped market awaits in home care, elderly care, and ICUs.
Commercial Readiness & IP Protection
1. Development Stage: Ready to Launch
- Regulatory Approved: Japan PMDA Class I (General Medical Device).
- Mass Production: Established at our “Mother Factory” (Tochigi Seiko Co., Ltd.) in Japan. High-quality injection molding lines are operational.
2. An Ironclad IP Portfolio
This system is protected not by a single patent, but by a multi-layered web of rights, making imitation extremely difficult.
- Foundational Patent: The core “Vacuuming” mechanism.
- System Patent: Enabling safe clinical application.
- Global Coverage: Patents granted/pending in Japan, USA, Europe, China, and India.
Partnership Opportunity
We are seeking Global Licensing Partners to expand this “Standard of Care” worldwide.
- India/Asia: Perfect for high-volume, cost-sensitive markets.
- US/EU: Ideal for high-value home care and infection control markets.